Nurix Therapeutics (NASDAQ:NRIX) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $32.00 target price on the stock.

Other equities analysts have also issued research reports about the company. Morgan Stanley set a $36.00 price objective on Nurix Therapeutics and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Stifel Nicolaus raised their price objective on Nurix Therapeutics from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. BTIG Research restated a “buy” rating and set a $30.00 price objective on shares of Nurix Therapeutics in a research note on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research note on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 target price on shares of Nurix Therapeutics in a report on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $30.46.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $16.49 on Monday. The stock’s fifty day moving average price is $15.76 and its two-hundred day moving average price is $15.93. Nurix Therapeutics has a one year low of $8.19 and a one year high of $22.50. The firm has a market cap of $1.71 billion, a PE ratio of -5.22 and a beta of 1.97.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The company had revenue of $6.25 million for the quarter, compared to the consensus estimate of $14.25 million. Sell-side analysts expect that Nurix Therapeutics will post -2.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,661 shares of the firm’s stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total value of $60,772.60. Following the sale, the chief financial officer owned 45,427 shares of the company’s stock, valued at approximately $754,088.20. This trade represents a 7.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gwenn Hansen sold 4,895 shares of the firm’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $81,257.00. Following the completion of the sale, the insider directly owned 83,672 shares in the company, valued at approximately $1,388,955.20. This represents a 5.53% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On Nurix Therapeutics

Large investors have recently modified their holdings of the business. Larson Financial Group LLC boosted its holdings in shares of Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after purchasing an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Nurix Therapeutics during the 4th quarter valued at $31,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Nurix Therapeutics during the 4th quarter valued at $33,000. Wexford Capital LP acquired a new stake in shares of Nurix Therapeutics during the 3rd quarter valued at $41,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Nurix Therapeutics by 118.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after acquiring an additional 3,475 shares in the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.